Agilent Technologies (A) 57.69 $A
Why Apple Pay Is So Important to Apple's Future
at The Street - Wed Sep 10, 3:10PM CDT
As Apple continues to expand beyond just iDevices, the massive profit and potential behind Apple Pay is one of the keys to the tech giant's revenue growth in the future.
TRADE NEWS: Keysight Technologies' New EXF One-Box Tester Scales with Volume Growth, Lowers Cost of Test in Femtocell Manufacturing
Business Wire - Wed Sep 10, 10:00AM CDT
Keysight Technologies, Inc. today announced the E6650A EXF wireless test set, the industry's first one-box tester dedicated to femtocell manufacturing. The EXF delivers the speed, performance and scalability needed to ramp up production and lower the cost of test. Validation with the latest cellular and WLAN chipsets reduces start-up time.
TRADE NEWS: Keysight Technologies Introduces 65-GSa/s High-Speed Arbitrary Waveform Generator
Business Wire - Wed Sep 10, 10:00AM CDT
Keysight Technologies, Inc. today added a 65-GSa/s, 20-GHz modular instrument to its portfolio of arbitrary waveform generators. The new high-speed, wide-bandwidth M8195A arbitrary waveform generator allows engineers to generate digital, multilevel (e.g. PAM4, MIPI C-PHY) signal scenarios and test their electrical and optical links with complex modulated signals up to 32 GBaud and beyond. This makes the M8195A the most versatile signal generator in the industry.
Global Chiral Chromatography Column Market Forecasts and Opportunities, 2018
M2 - Wed Sep 10, 3:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/47lplw/chiral) has announced the addition of the "Chiral Chromatography Column Market by type, Material, & by Application - Forecast to 2018" report to their offering. The chiral chromatography columns market size was $68 million in 2013 and is expected to reach $87.8 million by 2018, at a CAGR of 5.2% This report extensively covers chiral chromatography columns used by the pharmaceutical and life science industries. Volume analysis of the market has not been provided due to wide variations in prices of products, which vary with different indications. Over the years, the chiral chromatography columns market has witnessed various technological advancements that have led to an increase in the application areas of chiral chromatography columns. For instance, chiral chromatography columns are widely used in academic research laboratories and a number of industries, including pharmaceutical, biotechnology and biopharmaceutical, food and agriculture, environmental testing, and others. In the coming years, growth of the chiral chromatography columns market is likely to be centered in China, India, Japan, Brazil, and Mexico. These countries offer an array of opportunities for growth and are likely to serve as revenue pockets for the chromatography instrumentation market. All these countries offer high growth potential as compared to mature markets such as the U.S. and Canada. Growth in these markets is spurred by the growing number of pharmaceutical, biotechnology, and medical research industries in China, India, Japan, Brazil, and Mexico. Due to this, chiral chromatography columns companies are venturing into these regions. Scope Type - Empty - Pre-packed - Analytical - Preparative Material - Metal - Glass - Plastic Application - GC - LC (HPLC, UHPLC, Flash Chromatoraphy, UFLC) - TLC - SFC Companies Mentioned - Agilent Technologies - Daicel Corporation - Phenomenex, Inc. - Shimadzu Corporation - Sigma Aldrich Corporation - Thermo Fisher Scientific, Inc. - Waters Corporation For more information visit http://www.researchandmarkets.com/research/47lplw/chiral
Global Next Generation Sequencing (NGS) Market to 2020 - Platforms, Bioinformatics, Technology & Applications
M2 - Wed Sep 10, 3:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dhhxfb/next_generation) has announced the addition of the "Next Generation Sequencing (NGS) Market by Platforms, Bioinformatics , Technology & by Application - Global Forecast to 2020" report to their offering. The global next generation sequencing market is dynamic and witnessing many changes with new products being introduced. The global NGS market will be worth $2.5 billion in 2014 and is poised to reach $8.7 billion by 2020. The NGS market segments such as pre-sequencing products and services, NGS platforms, sequencing services and data analysis/bioinformatics are rapidly growing markets. The overall NGS market is flourishing by continuous innovations and developments in the market aimed at higher throughput, increased accuracy, and affordable costs. Developments in the pre-sequencing, cloud computing, and NGS bioinformatics solutions are major opportunities for this market. NGS services market is one of the key segments in the NGS market which is estimated to grow at a CAGR of 24.0% by 2020. The growth is driven by increasing demand in diagnostics and pharmaceutical and biotechnology companies. Sequencing by Synthesis technology will be the fastest growing technology in the coming years. SBS technology has wide applications in the NGS market and can be used for both single read and pair end libraries. Hence the demand for platforms such as HiSeq X Ten, NextSeq 500 and MiSeq is also high. Presequencing products and services market will also witness high growth and is estimated to grow at 23.5% CAGR in the next six years. The growth can be attributed to the increasing demand for presequencing consumables and instruments as the quality of the end product depends on the presequencing treatment. The growing need for standardized sample preparation solutions and increasing automation in the pre-sequencing workflow step are drivers of this market. The study is confined to platforms, consumables and services provided by top 4 companies, Illumina, Thermo Fisher (Life Technologies), Roche and Pacific Biosciences. It does not include other NGS platforms and miscellaneous consumables/reagents offered by other companies. Also, market estimation does not consider upcoming technologies or platforms. Scope Platforms - Illumina HiSeq - MiSeq - HiSeqX Ten - NextSeq 500 - Thermo Fisher Ion Proton/PGM Bioinformatics - Exome Sequencing - RNA-Seq - ChIP-Seq Technology - SBS - SMRT Application - Diagnostics - Personalized Medicine Companies Mentioned - 454 Life Sciences Corporation (Roche Holding Ag) - Agilent Technologies, Inc. - Bgi (Beijing Genomics Institute) - Biomatters, Ltd. - Clc Bio (Acquired By Qiagen) - Dnastar, Inc. - Gatc Biotech Ag - Genomatix Software Gmbh - Illumina, Inc. - Knome, Inc. - Life Technologies Corporation (Thermo Fisher Scientific) - Macrogen, Inc. - Oxford Nanopore Technologies, Ltd. - Pacific Biosciences - Partek Incorporated - Perkin Elmer, Inc. - Qiagen N.V. For more information visit http://www.researchandmarkets.com/research/dh...generation
TRADE NEWS: Keysight Technologies Introduces Logic Analyzer That Captures Industry's Highest Data Rates
Business Wire - Tue Sep 09, 11:00AM CDT
Keysight Technologies, Inc. today introduced the industry's highest-data-rate state-mode logic analyzer (up to 4 Gb/s), the industry's first solution for validating simultaneous read and write DDR4 traffic across all byte lanes captured from a DDR4 DIMM operating at data rates of more than 2.5 Gb/s.
Lab Automation Global Market - Forecast to 2020
PR Newswire Europe - Mon Sep 08, 12:10PM CDT
DUBLIN, Sept. 8, 2014 /PRNewswire/ -- Research and Markets [http://www.researchandmarkets.com/research/lrzpvt/lab_automation] has announced the addition of the "Lab Automation Global Market - Forecast to 2020" [http://www.researchandmarkets.com/research/lrzpvt/lab_automation] report to their offering.
Agilent Technologies to Present at Morgan Stanley Healthcare Conference
Business Wire - Fri Sep 05, 12:50PM CDT
Agilent Technologies Inc. (NYSE: A) today announced the following webcast for the investment community:
Global Biotechnology Reagents Market 2014-2018
M2 - Fri Sep 05, 8:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kjn7g3/global) has announced the addition of the "Global Biotechnology Reagents Market 2014-2018" report to their offering. The Global Biotechnology Reagents market to grow at a CAGR of 9.79 percent over the period 2013-2018. Biotechnology reagents are chemical compounds or substances that are added to a system to detect and examine another substance to provide a test reading. Reagents are generally used in laboratories to prepare, collect, and examine specimens from the human body for specific diagnostics. Biotechnology reagents are used in the field of research, molecular biotechnology, human immunology, genetics, diagnosis, biosciences, and education. An increase in biomedical research activities is one of the predominant trends in the market. New emerging fields such as DNA chips, metabolomics and combinational chemistry research drive the market growth. According to the report, high investment in R&D by biotechnology companies is one of the major drivers of the market. Biotechnology and pharmaceutical companies invest in the development and production of drugs, therapeutics, and diagnostics procedures for health and commercial applications. Further, the report states that one of the major challenges in the market is the presence of highly efficient automated instruments. Automated instruments enable optimal utilization of reagents, which has tempered the use of biotechnology reagents. These instruments minimize wastage and spill associated with traditional instruments as they are designed to avoid manual transfer of reagents from one container to another. Key Vendors - Agilent Technologies - BD Biosciences - Bio-Rad Laboratories - F. Hoffmann-La Roche - Sigma-Aldrich - Thermo Fisher Scientific Other Prominent Vendors - Abbott Diagnostics - Beckman Coulter (Subsidiary of Danaher) - EMD Millipore - GE Healthcare - QIAGEN - Takara Bio Key Questions Answered in this Report - What will the market size be in 2018 and what will the growth rate be? - What are the key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? For more information visit http://www.researchandmarkets.com/research/kjn7g3/global
Is It Time to Buy Danaher Corporation's Stock?
Lee Samaha, The Motley Fool - Motley Fool - Thu Sep 04, 5:30PM CDT
Diversified industrial conglomerate Danaher Corporation remains one of the highest quality stocks in the industrial sector, but there are question marks about its prospects going forward. What should investors do with a stock that has rewarded...
First Tech Federal Credit Union on Fast Track to ROI with Verian
PRWeb - Thu Sep 04, 10:07AM CDT
First Tech Federal Credit Union recently selected Verian's cloud-based, purchase-to-pay suite. The First Tech system, which has close to 1,000 end users, was implemented in less than 90 days. The implementation included multiple Verian software modules and ten unique system integrations.
Global Companion Diagnostic Technologies Market Opportunities and Forecasts 2013 - 2020
M2 - Thu Sep 04, 10:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3qr68q/global_companion) has announced the addition of the "Global Companion Diagnostic Technologies Market (Indication and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020" report to their offering. The global companion diagnostic market is expected to reach $3.5 billion by 2020, and it would grow at a CAGR of 20% from 2014 to 2020 Companion diagnostics market by indication is segmented into oncology, cardiovascular, CNS, autoimmune & inflammation, virology and others. Presently, majority of the companion diagnostics have been developed for cancer and thus, it is the major revenue generating segment in the overall CD indication market. Companion diagnostics have been developed for breast cancer, lung cancer, colorectal cancer, gastric cancer and melanomas. Companion diagnostics for breast cancer is the highest revenue generator mainly because there has been an increase in the incidences of breast cancer and many companion diagnostics have been developed for detection of the HER/neu biomarker for breast cancer. As of now, companion diagnostics for cardiovascular conditions, central nervous system conditions , inflammation and autoimmune diseases and viral diseases are very few, with a majority still in development stage; however, as more and more biomarkers are being discovered, there would be an increase in development of new companion diagnostics. Companion diagnostics market by technology is segmented into immmunohistochemistry and molecular diagnostics. Molecular diagnostics has been the most favored technology and it is expected that next generation sequencing and real-time PCR would drive the growth of this market owing to recent advancements in these technologies. KEY DELIVERABLES MARKET BY INDICATIONS - Oncology - Cardiovascular - Central Nervous System - Auto immune & Inflammation - Virology - Others MARKET BY TECHNOLOGY - Immunohistochemistry - Molecular diagnostics - In situ Hybridization - FISH - CISH - Real time PCR - Gene Sequencing COMPANY PROFILES - Abbott Laboratories - bioMerieux - Dako (Agilent Technologies) - Leica Microsystems - Life Technologies - Myriad Genetics - Qiagen - Resonance Health Ltd - Roche - Ventana Medical Systems For more information visit http://www.researchandmarkets.com/research/3q..._companion
TRADE NEWS: Agilent Technologies Introduces Tools for Next-Generation Genome Engineering
Business Wire - Thu Sep 04, 10:00AM CDT
Agilent Technologies Inc. (NYSE:A) today introduced SureGuide, the first in a new series of kits to advance genome editing and synthetic biology.
Future Horizons and Growth Strategies in the Global Flow Cytometry Market 2014: Supplier Shares and Country Forecasts
M2 - Thu Sep 04, 9:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r8nnxx/future_horizons) has announced the addition of the "Future Horizons and Growth Strategies in the Global Flow Cytometry Market 2014: Supplier Shares and Country Forecasts" report to their offering. This 7-country report will help current suppliers and potential market entrants identify and evaluate emerging opportunities in the flow cytometry markets during the next five years. The report explores future marketing and technological trends in seven countries; provides market share estimates, test volume forecasts, and instrument placements; compares features of major clinical and research flow cytometers; profiles competitors and emerging market entrants; and suggests specific product and marketing opportunities for flow cytometry instruments and reagents. Rational During the next five years, continued advances in molecular diagnostics, monoclonal antibodies, lasers and IT, as well as growing understanding of immunologic forces regulating systemic diseases, will have a profound impact on the flow cytometry markets worldwide. New molecular diagnostic and monoclonal antibody tests will facilitate existing procedures and provide basis for sensitive, specific and simple assays. The introduction of smaller and easy-to-operate laser systems will further expand applications of flow cytometry to routine clinical laboratories. Further advances in IT will reduce the cost of instrument manufacture, service warranty, and permit development of self-troubleshooting, autocalibration and other advanced features. Presently tedious analyses of chromosomal abnormalities, DNA content, and lymphocyte subsets will become more automated and routine. Key Topics Covered: I. Introduction II. Worldwide Market and Technology Overview III. France A. Executive Summary IV. Germany A. Executive Summary V. Italy A. Executive Summary VI. Japan A. Executive Summary VII. Spain A. Executive Summary VIII. U.K. A. Executive Summary IX. U.S. X. Major Product Development Opportunities XI. Design Criteria for Decentralized Testing Products XII. Alternative Market Penetration Strategies XIII. Potential Market Entry Barriers and Risks XIV. Competitive Assessments - Abbott - Beckman Coulter/Danaher - Becton Dickinson - Bio-Rad - CellaVision - Dako/Agilent Technologies - Horiba - Iris/Danaher - Ortho-Clinical Diagnostics - Nihon Kohden - Roche - Siemens - Sysmex For more information visit http://www.researchandmarkets.com/research/r8...e_horizons
Technical Updates, Clinical Trial Results, Certifications, Product Launches, and Grants - Research Reports on Avalonbay, Digital Realty, Boston Scientific, Agilent and Cigna
PR Newswire - Thu Sep 04, 7:40AM CDT
Today, Analysts Review released its research reports regarding Avalonbay Communities Inc. (NYSE: AVB), Digital Realty Trust Inc. (NYSE: DLR), Boston Scientific Corporation (NYSE: BSX), Agilent Technologies Inc. (NYSE: A) and Cigna Corp. (NYSE: CI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6195-100free.
Agilent Unveils ClearSeq AML Panels for Cancer Research - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 6:25PM CDT
Agilent (A) launched the first product of its ClearSeq family of advanced cancer research panels, ClearSeq AML, designed in association with Dr. Robert Ohgami and Dr. Daniel Arber at the Stanford Department of Pathology, Stanford University.
TRADE NEWS: Keysight Technologies Announces Best-in-Class Femto/Picoammeters and Electrometers for Research and Development of New Materials
Business Wire - Tue Sep 02, 10:00AM CDT
Keysight Technologies, Inc. today introduced the B2980A Series of femto/picoammeters and electrometers, the world's first graphical picoammeters and electrometers to confidently measure down to 0.01 fA which is 0.01 x 10-15 A, and up to 10 petaohms (P) which is 10 x 10(15) ohms.
Agilent Technologies Introduces Higher-Performance Q-TOF GC/MS System, Featuring Optimized Hardware/Software Capabilities
Business Wire - Tue Sep 02, 10:00AM CDT
Agilent Technologies Inc. (NYSE:A) today introduced the 7200B Quadrupole Time of Flight (Q-TOF) Gas Chromatography Mass Spectrometer (GC/MS) System. The system replaces the company's most advanced GC/QTOF, the 7200A, with new capabilities that will significantly boost laboratory performance.
Microlease Unveils Certified Pre-Owned Program
Business Wire - Tue Sep 02, 7:01AM CDT
Microlease, Inc. today announced the launch of Microlease Certified Pre-Owned, a comprehensive program to address growing customer demand for quality test instruments with guarantees and calibration. Microlease Certified Pre-Owned will include instruments from leading manufacturers including Keysight Technologies (formerly Agilent Technologies), Tektronix, JDSU, Anritsu, Rohde & Schwarz, and Keithley, among others.
Agilent Technologies the ClearSeq AML for next generation cancer research
M2 - Tue Sep 02, 3:51AM CDT
Agilent Technologies Inc (NYSE: A), a chemical analysis, life sciences, diagnostics, electronics and communications company, today introduced ClearSeq AML, the first product in the ClearSeq line of next-generation cancer research panels, which targets 48 selected exons in 20 of the most commonly mutated genes found in acute myeloid leukemia.
Why Apple Pay Is So Important to Apple's Future
at The Street - Wed Sep 10, 3:10PM CDT
As Apple continues to expand beyond just iDevices, the massive profit and potential behind Apple Pay is one of the keys to the tech giant's revenue growth in the future.
TRADE NEWS: Keysight Technologies' New EXF One-Box Tester Scales with Volume Growth, Lowers Cost of Test in Femtocell Manufacturing
Business Wire - Wed Sep 10, 10:00AM CDT
Keysight Technologies, Inc. today announced the E6650A EXF wireless test set, the industry's first one-box tester dedicated to femtocell manufacturing. The EXF delivers the speed, performance and scalability needed to ramp up production and lower the cost of test. Validation with the latest cellular and WLAN chipsets reduces start-up time.
TRADE NEWS: Keysight Technologies Introduces 65-GSa/s High-Speed Arbitrary Waveform Generator
Business Wire - Wed Sep 10, 10:00AM CDT
Keysight Technologies, Inc. today added a 65-GSa/s, 20-GHz modular instrument to its portfolio of arbitrary waveform generators. The new high-speed, wide-bandwidth M8195A arbitrary waveform generator allows engineers to generate digital, multilevel (e.g. PAM4, MIPI C-PHY) signal scenarios and test their electrical and optical links with complex modulated signals up to 32 GBaud and beyond. This makes the M8195A the most versatile signal generator in the industry.
Global Chiral Chromatography Column Market Forecasts and Opportunities, 2018
M2 - Wed Sep 10, 3:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/47lplw/chiral) has announced the addition of the "Chiral Chromatography Column Market by type, Material, & by Application - Forecast to 2018" report to their offering. The chiral chromatography columns market size was $68 million in 2013 and is expected to reach $87.8 million by 2018, at a CAGR of 5.2% This report extensively covers chiral chromatography columns used by the pharmaceutical and life science industries. Volume analysis of the market has not been provided due to wide variations in prices of products, which vary with different indications. Over the years, the chiral chromatography columns market has witnessed various technological advancements that have led to an increase in the application areas of chiral chromatography columns. For instance, chiral chromatography columns are widely used in academic research laboratories and a number of industries, including pharmaceutical, biotechnology and biopharmaceutical, food and agriculture, environmental testing, and others. In the coming years, growth of the chiral chromatography columns market is likely to be centered in China, India, Japan, Brazil, and Mexico. These countries offer an array of opportunities for growth and are likely to serve as revenue pockets for the chromatography instrumentation market. All these countries offer high growth potential as compared to mature markets such as the U.S. and Canada. Growth in these markets is spurred by the growing number of pharmaceutical, biotechnology, and medical research industries in China, India, Japan, Brazil, and Mexico. Due to this, chiral chromatography columns companies are venturing into these regions. Scope Type - Empty - Pre-packed - Analytical - Preparative Material - Metal - Glass - Plastic Application - GC - LC (HPLC, UHPLC, Flash Chromatoraphy, UFLC) - TLC - SFC Companies Mentioned - Agilent Technologies - Daicel Corporation - Phenomenex, Inc. - Shimadzu Corporation - Sigma Aldrich Corporation - Thermo Fisher Scientific, Inc. - Waters Corporation For more information visit http://www.researchandmarkets.com/research/47lplw/chiral
Global Next Generation Sequencing (NGS) Market to 2020 - Platforms, Bioinformatics, Technology & Applications
M2 - Wed Sep 10, 3:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dhhxfb/next_generation) has announced the addition of the "Next Generation Sequencing (NGS) Market by Platforms, Bioinformatics , Technology & by Application - Global Forecast to 2020" report to their offering. The global next generation sequencing market is dynamic and witnessing many changes with new products being introduced. The global NGS market will be worth $2.5 billion in 2014 and is poised to reach $8.7 billion by 2020. The NGS market segments such as pre-sequencing products and services, NGS platforms, sequencing services and data analysis/bioinformatics are rapidly growing markets. The overall NGS market is flourishing by continuous innovations and developments in the market aimed at higher throughput, increased accuracy, and affordable costs. Developments in the pre-sequencing, cloud computing, and NGS bioinformatics solutions are major opportunities for this market. NGS services market is one of the key segments in the NGS market which is estimated to grow at a CAGR of 24.0% by 2020. The growth is driven by increasing demand in diagnostics and pharmaceutical and biotechnology companies. Sequencing by Synthesis technology will be the fastest growing technology in the coming years. SBS technology has wide applications in the NGS market and can be used for both single read and pair end libraries. Hence the demand for platforms such as HiSeq X Ten, NextSeq 500 and MiSeq is also high. Presequencing products and services market will also witness high growth and is estimated to grow at 23.5% CAGR in the next six years. The growth can be attributed to the increasing demand for presequencing consumables and instruments as the quality of the end product depends on the presequencing treatment. The growing need for standardized sample preparation solutions and increasing automation in the pre-sequencing workflow step are drivers of this market. The study is confined to platforms, consumables and services provided by top 4 companies, Illumina, Thermo Fisher (Life Technologies), Roche and Pacific Biosciences. It does not include other NGS platforms and miscellaneous consumables/reagents offered by other companies. Also, market estimation does not consider upcoming technologies or platforms. Scope Platforms - Illumina HiSeq - MiSeq - HiSeqX Ten - NextSeq 500 - Thermo Fisher Ion Proton/PGM Bioinformatics - Exome Sequencing - RNA-Seq - ChIP-Seq Technology - SBS - SMRT Application - Diagnostics - Personalized Medicine Companies Mentioned - 454 Life Sciences Corporation (Roche Holding Ag) - Agilent Technologies, Inc. - Bgi (Beijing Genomics Institute) - Biomatters, Ltd. - Clc Bio (Acquired By Qiagen) - Dnastar, Inc. - Gatc Biotech Ag - Genomatix Software Gmbh - Illumina, Inc. - Knome, Inc. - Life Technologies Corporation (Thermo Fisher Scientific) - Macrogen, Inc. - Oxford Nanopore Technologies, Ltd. - Pacific Biosciences - Partek Incorporated - Perkin Elmer, Inc. - Qiagen N.V. For more information visit http://www.researchandmarkets.com/research/dh...generation
TRADE NEWS: Keysight Technologies Introduces Logic Analyzer That Captures Industry's Highest Data Rates
Business Wire - Tue Sep 09, 11:00AM CDT
Keysight Technologies, Inc. today introduced the industry's highest-data-rate state-mode logic analyzer (up to 4 Gb/s), the industry's first solution for validating simultaneous read and write DDR4 traffic across all byte lanes captured from a DDR4 DIMM operating at data rates of more than 2.5 Gb/s.
Lab Automation Global Market - Forecast to 2020
PR Newswire Europe - Mon Sep 08, 12:10PM CDT
DUBLIN, Sept. 8, 2014 /PRNewswire/ -- Research and Markets [http://www.researchandmarkets.com/research/lrzpvt/lab_automation] has announced the addition of the "Lab Automation Global Market - Forecast to 2020" [http://www.researchandmarkets.com/research/lrzpvt/lab_automation] report to their offering.
Agilent Technologies to Present at Morgan Stanley Healthcare Conference
Business Wire - Fri Sep 05, 12:50PM CDT
Agilent Technologies Inc. (NYSE: A) today announced the following webcast for the investment community:
Global Biotechnology Reagents Market 2014-2018
M2 - Fri Sep 05, 8:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kjn7g3/global) has announced the addition of the "Global Biotechnology Reagents Market 2014-2018" report to their offering. The Global Biotechnology Reagents market to grow at a CAGR of 9.79 percent over the period 2013-2018. Biotechnology reagents are chemical compounds or substances that are added to a system to detect and examine another substance to provide a test reading. Reagents are generally used in laboratories to prepare, collect, and examine specimens from the human body for specific diagnostics. Biotechnology reagents are used in the field of research, molecular biotechnology, human immunology, genetics, diagnosis, biosciences, and education. An increase in biomedical research activities is one of the predominant trends in the market. New emerging fields such as DNA chips, metabolomics and combinational chemistry research drive the market growth. According to the report, high investment in R&D by biotechnology companies is one of the major drivers of the market. Biotechnology and pharmaceutical companies invest in the development and production of drugs, therapeutics, and diagnostics procedures for health and commercial applications. Further, the report states that one of the major challenges in the market is the presence of highly efficient automated instruments. Automated instruments enable optimal utilization of reagents, which has tempered the use of biotechnology reagents. These instruments minimize wastage and spill associated with traditional instruments as they are designed to avoid manual transfer of reagents from one container to another. Key Vendors - Agilent Technologies - BD Biosciences - Bio-Rad Laboratories - F. Hoffmann-La Roche - Sigma-Aldrich - Thermo Fisher Scientific Other Prominent Vendors - Abbott Diagnostics - Beckman Coulter (Subsidiary of Danaher) - EMD Millipore - GE Healthcare - QIAGEN - Takara Bio Key Questions Answered in this Report - What will the market size be in 2018 and what will the growth rate be? - What are the key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? For more information visit http://www.researchandmarkets.com/research/kjn7g3/global
Is It Time to Buy Danaher Corporation's Stock?
Lee Samaha, The Motley Fool - Motley Fool - Thu Sep 04, 5:30PM CDT
Diversified industrial conglomerate Danaher Corporation remains one of the highest quality stocks in the industrial sector, but there are question marks about its prospects going forward. What should investors do with a stock that has rewarded...
First Tech Federal Credit Union on Fast Track to ROI with Verian
PRWeb - Thu Sep 04, 10:07AM CDT
First Tech Federal Credit Union recently selected Verian's cloud-based, purchase-to-pay suite. The First Tech system, which has close to 1,000 end users, was implemented in less than 90 days. The implementation included multiple Verian software modules and ten unique system integrations.
Global Companion Diagnostic Technologies Market Opportunities and Forecasts 2013 - 2020
M2 - Thu Sep 04, 10:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3qr68q/global_companion) has announced the addition of the "Global Companion Diagnostic Technologies Market (Indication and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020" report to their offering. The global companion diagnostic market is expected to reach $3.5 billion by 2020, and it would grow at a CAGR of 20% from 2014 to 2020 Companion diagnostics market by indication is segmented into oncology, cardiovascular, CNS, autoimmune & inflammation, virology and others. Presently, majority of the companion diagnostics have been developed for cancer and thus, it is the major revenue generating segment in the overall CD indication market. Companion diagnostics have been developed for breast cancer, lung cancer, colorectal cancer, gastric cancer and melanomas. Companion diagnostics for breast cancer is the highest revenue generator mainly because there has been an increase in the incidences of breast cancer and many companion diagnostics have been developed for detection of the HER/neu biomarker for breast cancer. As of now, companion diagnostics for cardiovascular conditions, central nervous system conditions , inflammation and autoimmune diseases and viral diseases are very few, with a majority still in development stage; however, as more and more biomarkers are being discovered, there would be an increase in development of new companion diagnostics. Companion diagnostics market by technology is segmented into immmunohistochemistry and molecular diagnostics. Molecular diagnostics has been the most favored technology and it is expected that next generation sequencing and real-time PCR would drive the growth of this market owing to recent advancements in these technologies. KEY DELIVERABLES MARKET BY INDICATIONS - Oncology - Cardiovascular - Central Nervous System - Auto immune & Inflammation - Virology - Others MARKET BY TECHNOLOGY - Immunohistochemistry - Molecular diagnostics - In situ Hybridization - FISH - CISH - Real time PCR - Gene Sequencing COMPANY PROFILES - Abbott Laboratories - bioMerieux - Dako (Agilent Technologies) - Leica Microsystems - Life Technologies - Myriad Genetics - Qiagen - Resonance Health Ltd - Roche - Ventana Medical Systems For more information visit http://www.researchandmarkets.com/research/3q..._companion
TRADE NEWS: Agilent Technologies Introduces Tools for Next-Generation Genome Engineering
Business Wire - Thu Sep 04, 10:00AM CDT
Agilent Technologies Inc. (NYSE:A) today introduced SureGuide, the first in a new series of kits to advance genome editing and synthetic biology.
Future Horizons and Growth Strategies in the Global Flow Cytometry Market 2014: Supplier Shares and Country Forecasts
M2 - Thu Sep 04, 9:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r8nnxx/future_horizons) has announced the addition of the "Future Horizons and Growth Strategies in the Global Flow Cytometry Market 2014: Supplier Shares and Country Forecasts" report to their offering. This 7-country report will help current suppliers and potential market entrants identify and evaluate emerging opportunities in the flow cytometry markets during the next five years. The report explores future marketing and technological trends in seven countries; provides market share estimates, test volume forecasts, and instrument placements; compares features of major clinical and research flow cytometers; profiles competitors and emerging market entrants; and suggests specific product and marketing opportunities for flow cytometry instruments and reagents. Rational During the next five years, continued advances in molecular diagnostics, monoclonal antibodies, lasers and IT, as well as growing understanding of immunologic forces regulating systemic diseases, will have a profound impact on the flow cytometry markets worldwide. New molecular diagnostic and monoclonal antibody tests will facilitate existing procedures and provide basis for sensitive, specific and simple assays. The introduction of smaller and easy-to-operate laser systems will further expand applications of flow cytometry to routine clinical laboratories. Further advances in IT will reduce the cost of instrument manufacture, service warranty, and permit development of self-troubleshooting, autocalibration and other advanced features. Presently tedious analyses of chromosomal abnormalities, DNA content, and lymphocyte subsets will become more automated and routine. Key Topics Covered: I. Introduction II. Worldwide Market and Technology Overview III. France A. Executive Summary IV. Germany A. Executive Summary V. Italy A. Executive Summary VI. Japan A. Executive Summary VII. Spain A. Executive Summary VIII. U.K. A. Executive Summary IX. U.S. X. Major Product Development Opportunities XI. Design Criteria for Decentralized Testing Products XII. Alternative Market Penetration Strategies XIII. Potential Market Entry Barriers and Risks XIV. Competitive Assessments - Abbott - Beckman Coulter/Danaher - Becton Dickinson - Bio-Rad - CellaVision - Dako/Agilent Technologies - Horiba - Iris/Danaher - Ortho-Clinical Diagnostics - Nihon Kohden - Roche - Siemens - Sysmex For more information visit http://www.researchandmarkets.com/research/r8...e_horizons
Technical Updates, Clinical Trial Results, Certifications, Product Launches, and Grants - Research Reports on Avalonbay, Digital Realty, Boston Scientific, Agilent and Cigna
PR Newswire - Thu Sep 04, 7:40AM CDT
Today, Analysts Review released its research reports regarding Avalonbay Communities Inc. (NYSE: AVB), Digital Realty Trust Inc. (NYSE: DLR), Boston Scientific Corporation (NYSE: BSX), Agilent Technologies Inc. (NYSE: A) and Cigna Corp. (NYSE: CI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6195-100free.
Agilent Unveils ClearSeq AML Panels for Cancer Research - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 6:25PM CDT
Agilent (A) launched the first product of its ClearSeq family of advanced cancer research panels, ClearSeq AML, designed in association with Dr. Robert Ohgami and Dr. Daniel Arber at the Stanford Department of Pathology, Stanford University.
TRADE NEWS: Keysight Technologies Announces Best-in-Class Femto/Picoammeters and Electrometers for Research and Development of New Materials
Business Wire - Tue Sep 02, 10:00AM CDT
Keysight Technologies, Inc. today introduced the B2980A Series of femto/picoammeters and electrometers, the world's first graphical picoammeters and electrometers to confidently measure down to 0.01 fA which is 0.01 x 10-15 A, and up to 10 petaohms (P) which is 10 x 10(15) ohms.
Agilent Technologies Introduces Higher-Performance Q-TOF GC/MS System, Featuring Optimized Hardware/Software Capabilities
Business Wire - Tue Sep 02, 10:00AM CDT
Agilent Technologies Inc. (NYSE:A) today introduced the 7200B Quadrupole Time of Flight (Q-TOF) Gas Chromatography Mass Spectrometer (GC/MS) System. The system replaces the company's most advanced GC/QTOF, the 7200A, with new capabilities that will significantly boost laboratory performance.
Microlease Unveils Certified Pre-Owned Program
Business Wire - Tue Sep 02, 7:01AM CDT
Microlease, Inc. today announced the launch of Microlease Certified Pre-Owned, a comprehensive program to address growing customer demand for quality test instruments with guarantees and calibration. Microlease Certified Pre-Owned will include instruments from leading manufacturers including Keysight Technologies (formerly Agilent Technologies), Tektronix, JDSU, Anritsu, Rohde & Schwarz, and Keithley, among others.
Agilent Technologies the ClearSeq AML for next generation cancer research
M2 - Tue Sep 02, 3:51AM CDT
Agilent Technologies Inc (NYSE: A), a chemical analysis, life sciences, diagnostics, electronics and communications company, today introduced ClearSeq AML, the first product in the ClearSeq line of next-generation cancer research panels, which targets 48 selected exons in 20 of the most commonly mutated genes found in acute myeloid leukemia.
